Healthcare company Trellus Health plc (AIM: TRLS) announced on Monday that it has renewed its licensing agreement with biopharmaceutical company Pfizer Inc, extending the use of its patient support educational content within Pfizer's digital application for inflammatory bowel disease.

The original agreement, signed in the second quarter of 2024, enables Pfizer to incorporate Trellus Health's resilience-based content into its IBD platform. The renewal supports the company's ongoing commercial strategy in digital health solutions for chronic conditions.

Trellus Health reported a reduced average monthly cash burn of approximately USD300,000 as of March 2026. The agreement renewal, alongside a loan from scientific co-founder Laurie Keefer, is expected to extend the company's cash runway into May 2026, while discussions on further funding options continue.

The company's Trellus Elevate platform combines data analytics with personalised resilience programmes to support patients with chronic conditions, initially targeting gastrointestinal diseases such as IBD.